FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172885009> ?p ?o ?g. }

• W3172885009 endingPage "TPS8585" @default.
• W3172885009 startingPage "TPS8585" @default.
• W3172885009 abstract "TPS8585 Background: Non-small cell lung cancer (NSCLC) is the most common cause of cancer death worldwide highlighting the importance of improving current therapeutic options. In particular, elderly and frail patients are not only underrepresented in clinical trials, but also frequently do not receive standard treatment regimens due to comorbidities. For example, patients with unresectable stage III NSCLC who are unfit for chemotherapy (CHT) do not benefit from the recent seminal therapy algorithm change for this disease, i.e. consolidation therapy with the immune checkpoint inhibitor (ICI) durvalumab after combined radiochemotherapy (RChT). Instead, these patients are treated with radiotherapy only, raising the serious concern of undertreatment. This issue is addressed by the TRADE-hypo clinical trial that investigates a novel therapy option for NSCLC stage III patients not capable of receiving CHT. To this end, thoracic radiotherapy (TRT) is administered together with durvalumab, employing the synergism created by the combination of restoring anti-tumor immune response by the ICI with the induction of immunogenicity by irradiation. The latter effect has been suggested to be further boosted by hypofractionated radiotherapy, which could also be more practicable for the patient. Taken these considerations into account, the TRADE-hypo trial addresses safety and efficacy of durvalumab therapy combined with either conventional or hypofractionated TRT. Methods: The TRADE-hypo trial is a prospective, randomized, open-label, multicentric phase II trial. Eligible patients are diagnosed with unresectable stage III NSCLC and not capable of receiving sequential RChT due to high vulnerability as reflected by a poor performance status (ECOG 2 or ECOG1 and CCI≥ 1) and/or high age (≥ 70)]. Two treatment groups are evaluated: Both receive durvalumab (1,5000 mg, Q4W) for up to 12 months. In the CON-group this is combined with conventionally fractionated TRT (30 x 2 Gy), while in the HYPO-group patients are treated with hypofractionated TRT (20 x 2.75 Gy). In the HYPO-arm, a safety stop-and-go lead-in phase precedes full enrollment. Here, patients are closely monitored with regard to toxicity (i.e., pneumonitis grade ≥ 3 within 8 weeks after TRT) in small cohorts of 6. The primary objective of the trial is safety and tolerability. As a primary efficacy endpoint, the objective response rate after 3 months will be evaluated. Further endpoints are additional parameters of safety and efficacy, as well as the comprehensive collection of biomaterials to be analyzed regarding treatment-induced changes and potential novel biomarkers. As of February 10, 2021, 9 patients of planned 88 patients have been enrolled in the TRADE-hypo trial. Clinical trial information: NCT04351256." @default.
• W3172885009 created "2021-06-22" @default.
• W3172885009 creator A5012074807 @default.
• W3172885009 creator A5013299722 @default.
• W3172885009 creator A5013804417 @default.
• W3172885009 creator A5014427777 @default.
• W3172885009 creator A5020023624 @default.
• W3172885009 creator A5024537192 @default.
• W3172885009 creator A5025473299 @default.
• W3172885009 creator A5028935333 @default.
• W3172885009 creator A5029083427 @default.
• W3172885009 creator A5035949463 @default.
• W3172885009 creator A5036628203 @default.
• W3172885009 creator A5039229070 @default.
• W3172885009 creator A5040589443 @default.
• W3172885009 creator A5057065901 @default.
• W3172885009 creator A5061889546 @default.
• W3172885009 creator A5063720872 @default.
• W3172885009 creator A5064576653 @default.
• W3172885009 creator A5070459418 @default.
• W3172885009 creator A5076463194 @default.
• W3172885009 creator A5080547151 @default.
• W3172885009 creator A5085218781 @default.
• W3172885009 date "2021-05-20" @default.
• W3172885009 modified "2023-09-26" @default.
• W3172885009 title "Thoracic radiotherapy PLUS durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy: Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy—The TRADE-hypo trial." @default.
• W3172885009 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.tps8585" @default.
• W3172885009 hasPublicationYear "2021" @default.
• W3172885009 type Work @default.
• W3172885009 sameAs 3172885009 @default.
• W3172885009 citedByCount "1" @default.
• W3172885009 countsByYear W31728850092022 @default.
• W3172885009 crossrefType "journal-article" @default.
• W3172885009 hasAuthorship W3172885009A5012074807 @default.
• W3172885009 hasAuthorship W3172885009A5013299722 @default.
• W3172885009 hasAuthorship W3172885009A5013804417 @default.
• W3172885009 hasAuthorship W3172885009A5014427777 @default.
• W3172885009 hasAuthorship W3172885009A5020023624 @default.
• W3172885009 hasAuthorship W3172885009A5024537192 @default.
• W3172885009 hasAuthorship W3172885009A5025473299 @default.
• W3172885009 hasAuthorship W3172885009A5028935333 @default.
• W3172885009 hasAuthorship W3172885009A5029083427 @default.
• W3172885009 hasAuthorship W3172885009A5035949463 @default.
• W3172885009 hasAuthorship W3172885009A5036628203 @default.
• W3172885009 hasAuthorship W3172885009A5039229070 @default.
• W3172885009 hasAuthorship W3172885009A5040589443 @default.
• W3172885009 hasAuthorship W3172885009A5057065901 @default.
• W3172885009 hasAuthorship W3172885009A5061889546 @default.
• W3172885009 hasAuthorship W3172885009A5063720872 @default.
• W3172885009 hasAuthorship W3172885009A5064576653 @default.
• W3172885009 hasAuthorship W3172885009A5070459418 @default.
• W3172885009 hasAuthorship W3172885009A5076463194 @default.
• W3172885009 hasAuthorship W3172885009A5080547151 @default.
• W3172885009 hasAuthorship W3172885009A5085218781 @default.
• W3172885009 hasConcept C121608353 @default.
• W3172885009 hasConcept C126322002 @default.
• W3172885009 hasConcept C141071460 @default.
• W3172885009 hasConcept C143998085 @default.
• W3172885009 hasConcept C146357865 @default.
• W3172885009 hasConcept C151730666 @default.
• W3172885009 hasConcept C2776694085 @default.
• W3172885009 hasConcept C2777701055 @default.
• W3172885009 hasConcept C2777742743 @default.
• W3172885009 hasConcept C2780030458 @default.
• W3172885009 hasConcept C509974204 @default.
• W3172885009 hasConcept C535046627 @default.
• W3172885009 hasConcept C71924100 @default.
• W3172885009 hasConcept C86803240 @default.
• W3172885009 hasConceptScore W3172885009C121608353 @default.
• W3172885009 hasConceptScore W3172885009C126322002 @default.
• W3172885009 hasConceptScore W3172885009C141071460 @default.
• W3172885009 hasConceptScore W3172885009C143998085 @default.
• W3172885009 hasConceptScore W3172885009C146357865 @default.
• W3172885009 hasConceptScore W3172885009C151730666 @default.
• W3172885009 hasConceptScore W3172885009C2776694085 @default.
• W3172885009 hasConceptScore W3172885009C2777701055 @default.
• W3172885009 hasConceptScore W3172885009C2777742743 @default.
• W3172885009 hasConceptScore W3172885009C2780030458 @default.
• W3172885009 hasConceptScore W3172885009C509974204 @default.
• W3172885009 hasConceptScore W3172885009C535046627 @default.
• W3172885009 hasConceptScore W3172885009C71924100 @default.
• W3172885009 hasConceptScore W3172885009C86803240 @default.
• W3172885009 hasIssue "15_suppl" @default.
• W3172885009 hasLocation W31728850091 @default.
• W3172885009 hasOpenAccess W3172885009 @default.
• W3172885009 hasPrimaryLocation W31728850091 @default.
• W3172885009 hasRelatedWork W1535958986 @default.
• W3172885009 hasRelatedWork W167319750 @default.
• W3172885009 hasRelatedWork W1987468340 @default.
• W3172885009 hasRelatedWork W2047967234 @default.
• W3172885009 hasRelatedWork W2376593068 @default.
• W3172885009 hasRelatedWork W2390264150 @default.
• W3172885009 hasRelatedWork W2404042595 @default.
• W3172885009 hasRelatedWork W3115829157 @default.
• W3172885009 hasRelatedWork W4220939315 @default.
• W3172885009 hasRelatedWork W4319224783 @default.
• W3172885009 hasVolume "39" @default.
• W3172885009 isParatext "false" @default.

• next